ESC 2013: Medtronic's Symplicity hypertension treatment still promising at 1 and 3 years

September 3, 2013 by Ingrid Mezo

A pair of Medtronic studies support the Symplicity renal denervation system in treatment of patients with drug-resistant hypertension, with promising results at 1 and 3 years following treatment.

ESC 2013: Medtronic renal denervation going strong at 3 years

New data on Medtronic's (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.

A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.

Sign up to get our free newsletters delivered right to your inbox.

In 1-year data from the SYMPLICITY registry major complications or serious adverse events associated with denervation were very rare among the more than 1,150 patient enrolled, Medtronic announced. At 6 months only 1 patient needed a procedural dissection and only 1 patient required a re-intervention, representing a 0.09% adverse event rate for each, the Minneapolis-based firm noted.

Symplicity, which delivers radio frequency energy to the renal artery, significantly reduced blood pressure and kept it lower compared to baseline at all time-points up to 12 months when blood pressure was measured both in-office and on-the-go, Medtronic said.